The Pharma Data

AUGUST 9, 2021

The pre-clinical animal trials of the intranasal vaccine showed a reduction in both the impact of the disease itself and transmission of the virus. This should prevent both clinical disease and virus transmission, to halt the spread of the COVID-19 pandemic.

Vaccine 52

Vaccine Virus Immune Response Disease 52

The Pharma Data

DECEMBER 8, 2020

The efficacy rating followed an interim report of ongoing human trials conducted in that country, CNBC reported. In August, the company reported the vaccine candidate triggered antibody-based immune responses in early and mid-stage trials. The vaccine was also demonstrating a strong safety profile.

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

The Pharma Data

AUGUST 16, 2021

Vaccination is our most effective means of preventing COVID-19 infection – especially severe disease and hospitalization – and its profound impact on protecting lives is indisputable. We continuously strive to stay at least one step ahead of the virus. adult participants from the Phase 1 trial of the two-dose series.

Vaccine 52

Vaccine FDA Virus Immune Response 52

NIH Director's Blog: Drug Development

FEBRUARY 16, 2021

hospitals are stretched to the limit trying to help people battling serious cases of COVID-19. Cutting through the usual red tape and working with an intense sense of purpose, the partnership took a mere matter of weeks to set up its first four clinical trials. Credit: NIH Right now, many U.S.

Clinical Trials 52

Clinical Trials Hospitals Vaccine Trials 52

NIH Director's Blog: Drug Development

FEBRUARY 1, 2022

The researchers had been intrigued by an earlier clinical trial testing the ACE2 decoy strategy [2]. However, in this earlier attempt, the clinical trial found no reduction in mortality. The ACE2 drug candidate, which is soluble and degrades in the body, also proved ineffective in neutralizing the virus.

Virus 52

Virus Engineering Clinical Trials Immune Response 52

The Pharma Data

FEBRUARY 23, 2022

* Final analysis of the global VAT02 booster trial confirms universal ability to boost neutralizing antibodies 18- to 30-fold across vaccine platforms (mRNA, adenovirus). * About VAT08 and VAT02 The Phase 3 trial, VAT08 is evaluating a 10µg antigen formulation of the SARS-CoV-2 adjuvanted recombinant protein-based vaccine?for

Vaccine 52

Vaccine Virus Trials Immune Response 52

The Pharma Data

MARCH 25, 2021

TAK-003 is Being Studied for the Prevention of Dengue Due to any Dengue Virus Serotype in Individuals Ages Four to 60. Dengue outbreaks, which result in half a million hospitalizations globally each year, can overwhelm communities and governments because of the broad impact on the health care system. 4,5 Efficacy varied by serotype.

Vaccine 52

Vaccine Virus Trials Hospitals 52

The Pharma Data

DECEMBER 16, 2020

The technology leveraged to create the vaccine does not require the actual virus, according to CNN. Instead, it uses a genetic code, which tricks the body into developing an immune response to the virus. An efficacy analysis of a Phase III trial of the vaccine was made available at the end of November by Moderna.

Vaccine 52

Vaccine Immune Response FDA FDA Approval 52

Broad Institute

AUGUST 7, 2023

Related people Paul Blainey Nir Hacohen A signaling protein known as STING is a critical player in the human immune system, detecting signs of danger within cells and then activating a variety of defense mechanisms.

Regulations 91

Regulations Engineering Clinical Trials DNA 91

The Pharma Data

JANUARY 4, 2021

Data from Moderna’s trials showed that people between 18 and 55 who received two 50-microgram doses had an “identical immune response” to the standard of two 100-microgram doses, Dr. Moncef Slaoui explained, the Times reported. But a faster-spreading virus could swamp hospitals with seriously ill patients.

Vaccine 52

Vaccine Immune Response Virus Hospitals 52

The Pharma Data

JANUARY 11, 2021

In clinical trials, it could detect COVID-19 with 90%+ accuracy in about two minutes. . By the end of January, Johnson & Johnson is expected to deliver preliminary trial results for its one-dose COVID-19 vaccine candidate. . I-SPY COVID-19 is assessing multiple drugs for critical COVID-19 hospitalized or ICU patients.

Vaccine 52

Vaccine Clinical Trials Immune Response Virus 52

The Pharma Data

MARCH 29, 2022

Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months Evusheld retains neutralising activity against the Omicron BA.2 1-3 Evusheld was generally well-tolerated in the trial. 2 subvariant, now the dominant strain in Europe. Christoph D.

Vaccine 52

Vaccine Virus Immune Response Government 52

Agency IQ

DECEMBER 1, 2023

Furthermore, the guidance offered a list of updated clinical outcome measures and offered insight on FDA’s evolving view of decentralized clinical trials and the use of real-world data to supplement trials. Lastly, the revised guidance briefly discussed trials meant to assess drugs intended for prevention of Covid-19.

FDA 40

FDA Clinical Trials Vaccine Trials 40

The Pharma Data

JANUARY 5, 2021

“These are all reasonable questions to consider and evaluate in clinical trials. But Marks and Hahn said these preliminary findings covered only a few people who were not followed long enough to see if their immune responses held up over time. But a faster-spreading virus could swamp hospitals with seriously ill patients.

Vaccine 52

Vaccine FDA Virus Immune Response 52

The Pharma Data

JANUARY 3, 2021

This trial is the first to evaluate nasally administered Foralumab to improve the immune system’s fight against coronaviruses. The last patients in the trial received their final dose on 21 December 2020. The topline data from the trial is expected to be available in January 2021.

Clinical Trials 40

Clinical Trials Science Treatment Trials 40

The Pharma Data

NOVEMBER 1, 2020

Trial facilitated with coll a boration of Harvard Medical School and one of the world’s top Neurologist, Dr. Howard Weiner. This clinical trial will be coordinated by the team at the INTRIALS, a leading, full-service Latin America Clinical Research Organization (CRO), based in Sao Paulo City, Brazil.

Clinical Trials 52

Clinical Trials Trials Medical Schools Hospitals 52

The Pharma Data

SEPTEMBER 17, 2020

The new Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in patients who have been exposed to the virus. The majority of current candidate vaccines aim to induce an antibody response against the spike protein. “As The test targets antibodies against the spike protein.

Vaccine 52

Vaccine Virus Clinical Trials Immune Response 52

The Pharma Data

OCTOBER 14, 2020

Food and Drug Administration (FDA) to begin a Phase I clinical trial of hAd5-COVID-19, the company’s novel COVID-19 vaccine candidate that targets both the inner nucleocapsid (N), engineered to activate T cells, and outer spike (S) protein, engineered to activate antibodies against the coronavirus (SARS-CoV-2). i,ii,iii,iv.

Vaccine 52

Vaccine Trials FDA Clinical Trials 52

The Pharma Data

JANUARY 15, 2021

. “People with all kinds of cardiovascular risk factors and disease should definitely get vaccinated to protect themselves and their families from COVID-19,” said Dr. Mitchell Elkind, a professor of neurology and epidemiology at NewYork-Presbyterian Hospital/Columbia University Irving Medical Center in New York City.

Vaccine 52

Vaccine Virus Immune Response Disease 52

The Pharma Data

JANUARY 24, 2021

In these studies, both V590 and V591 were generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines. Molnupiravir is currently being evaluated in Phase 2/3 clinical trials in both the hospital and out-patient settings.

Vaccine 52

Vaccine Immune Response Virus Production 52

The Pharma Data

NOVEMBER 17, 2020

Mymetics, through its collaborator, the Department of Pneumology at the Inselspital, Bern University Hospital, in Switzerland, have received a grant from the Swiss Innovation Agency (Innosuisse) to investigate Mymetics’ intranasal Covid-19 vaccine candidates in preclinical studies. ” About Mymetics.

Vaccine 40

Vaccine Hospitals Immune Response Compliance 40

The Pharma Data

DECEMBER 18, 2020

. “ With the availability of two vaccines now for the prevention of COVID-19, the FDA has taken another crucial step in the fight against this global pandemic that is causing vast numbers of hospitalizations and deaths in the United States each day,” said FDA Commissioner Stephen M. Hahn , M.D. It is mandatory for ModernaTX, Inc.

Vaccine 52

Vaccine FDA Clinical Trials FDA Approval 52

The Pharma Data

NOVEMBER 29, 2020

HB-101, a non-replicating arenavirus vaccine, is being investigated in a double-blind Phase 2 clinical trial (NCT03629080) to assess safety, immunogenicity and efficacy in individuals receiving a kidney transplant from a living donor. Safety and tolerability were evaluated in 69 participants who were enrolled in the trial by the cut-off date.

Vaccine 52

Vaccine Clinical Trials Disease Therapies 52

The Pharma Data

MARCH 3, 2022

Pfizer will publish outcomes from this clinical trial at a future date. If approved by the FDA, this maternal immunization has the potential to be the first vaccine candidate to help protect infants in their vulnerable first months of life from disease caused by this highly-contagious virus. Pfizer Inc.

Virus 52

Virus Vaccine Clinical Trials FDA 52

The Pharma Data

JUNE 26, 2021

Sanofi and Translate Bio initiate Phase 1 clinical trial of mRNA influenza vaccine. The trial will evaluate the safety and immunogenicity of a monovalent flu vaccine candidate coding for the hemagglutinin protein of the A/H3N2 strain of the influenza virus. JUNE 22 , 2021.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

SEPTEMBER 2, 2021

The Phase 3 RENOIR trial of RSVpreF is a global, randomized, double-blind, placebo-controlled study that expects to enroll approximately 30,000 participants 60 years and older. Respiratory syncytial virus (RSV) is a common and pervasive cause of acute respiratory illness. Burden of RSV. 2 In the U.S.,

Clinical Trials 52

Clinical Trials Trials Vaccine Virus 52

Codon

FEBRUARY 13, 2024

doi: 10.2210/rcsb_pdb/goodsell-gallery-048 The Virus that Cures It’s been over 25 years since the science magazine Discover first ran an extraordinary article about how a long-forgotten medical treatment, used in the former Soviet country of Georgia, could save us from the growing threat of untreatable, drug-resistant infections.

Therapies 138

Therapies DNA Virus Clinical Trials 138

The Pharma Data

NOVEMBER 20, 2020

The clinical evidence from Regeneron’s outpatient trial suggests that monoclonal antibodies such as casirivimab and imdevimab have the greatest benefit when given early after diagnosis and in patients who have not yet mounted their own immune response or who have high viral load. Yancopoulos, M.D.,

Therapies 52

Therapies FDA Clinical Trials Hospitals 52

The Pharma Data

NOVEMBER 21, 2020

The clinical evidence from Regeneron’s outpatient trial suggests that monoclonal antibodies such as REGEN-COV2 have the greatest benefit when given early after diagnosis and in patients who have not yet mounted their own immune response or who have high viral load. Yancopoulos , M.D.,

FDA 40

FDA Clinical Trials Hospitals Government 40

The Pharma Data

NOVEMBER 9, 2020

Trial Also Met the Primary Endpoint in Patients With Low Levels of Eosinophils. In the subgroup of patients with baseline eosinophil counts less than 300 cells per microliter, the trial met the primary endpoint with tezepelumab demonstrating a statistically significant and clinically meaningful reduction in AAER.

Trials 52

Trials Production Clinical Trials Government 52

The Pharma Data

JANUARY 13, 2021

13, 2021 — A single-shot COVID-19 vaccine from Johnson & Johnson has shown very strong results in early clinical trials, potentially providing a significant boost to U.S. The vaccine produced an immune response of all 805 clinical trial participants within two months of inoculation, according to results published Jan.

Vaccine 40

Vaccine Trials Immune Response Clinical Trials 40

The Pharma Data

OCTOBER 18, 2020

Food and Drug Administration (FDA) to begin the Phase 2 portion of its Phase 2/3 clinical study of its investigational drug, EB05, for the treatment of hospitalized COVID-19 patients. Hospitals interested in participating in the study should contact info@edesabiotech.com or visit www.clinicaltrials.gov (Identifier: NCT04401475).

Immune Response 40

Immune Response Hospitals Virus Treatment 40

The Pharma Data

SEPTEMBER 25, 2020

Johnson & Johnson Posts Interim Results from Phase 1/2a Clinical Trial of its Janssen COVID-19 Vaccine Candidate. Johnson & Johnson Posts Interim Results from Phase 1/2a Clinical Trial of its Janssen COVID-19 Vaccine Candidate. Immune responses were similar across the age groups studied, including older adults.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

NOVEMBER 24, 2020

“These are immune responses, so if you feel something after vaccination, you should expect to feel that. Vaccines work to fight disease by producing an immune response within the body. Drug giant AstraZeneca announcing that late-stage clinical trials of its coronavirus shot showed it to be 70.4%

Vaccine 52

Vaccine Immune Response Virus Hospitals 52

The Pharma Data

SEPTEMBER 7, 2021

Bristol Myers Squibb has a global exclusive license to develop, manufacture and commercialize the Rockefeller University’s novel monoclonal antibody (“mAb”) duo treatment that neutralizes the SARS-CoV-2 virus for therapy or prevention of COVID-19. Our Clinical Trials and Research. All of our U.S.

Clinical Trials 52

Clinical Trials Vaccine Virus Trials 52

The Pharma Data

SEPTEMBER 5, 2021

“This new analysis from NAVIGATOR is exciting for the up to one in five severe asthma patients who have comorbid nasal polyps,” said Professor Andrew Menzies-Gow, director of the Lung Division, Royal Brompton Hospital, London, UK, the principal investigator of the NAVIGATOR trial.

Trials 52

Trials Clinical Trials Therapies Treatment 52

Drug Discovery World

AUGUST 1, 2023

As such, the company has entered into a sponsored research agreement with the Children’s Hospital of Philadelphia (CHOP) in the US to develop a TUBB4A-related leukodystrophy treatment from ASOs. This Phase I trial will test the experimental vaccine, known as H1ssF-3928 mRNA-LNP, for safety and its ability to induce an immune response.

RNA 130

RNA Vaccine Drugs Disease 130